Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;31(9):1645-1669.
doi: 10.1007/s00198-020-05378-0. Epub 2020 May 1.

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

D Cornelissen  1 , S de Kunder  2 , L Si  3 , J-Y Reginster  4   5 , S Evers  6   7 , A Boonen  6   8 , M Hiligsmann  6 ; European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
Affiliations

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

D Cornelissen et al. Osteoporos Int. 2020 Sep.

Abstract

An earlier systematic review on interventions to improve adherence and persistence was updated. Fifteen studies investigating the effectiveness of patient education, drug regimen, monitoring and supervision, and interdisciplinary collaboration as a single or multi-component intervention were appraised. Multicomponent interventions with active patient involvement were more effective.

Introduction: This study was conducted to update a systematic literature review on interventions to improve adherence to anti-osteoporosis medications.

Methods: A systematic literature review was carried out in Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, ClinicalTrials.gov , NHS Centre for Review and Dissemination, CINHAL, and PsycINFO to search for original studies that assessed interventions to improve adherence (comprising initiation, implementation, and discontinuation) and persistence to anti-osteoporosis medications among patients with osteoporosis, published between July 2012 and December 2018. Quality of included studies was assessed.

Results: Of 585 studies initially identified, 15 studies fulfilled the inclusion criteria of which 12 were randomized controlled trials. Interventions were classified as (1) patient education (n = 9), (2) drug regimen (n = 3), (3) monitoring and supervision (n = 2), and (4) interdisciplinary collaboration (n = 1). In most subtypes of interventions, mixed results on adherence (and persistence) were found. Multicomponent interventions based on patient education and counseling were the most effective interventions when aiming to increase adherence and/or persistence to osteoporosis medications.

Conclusion: This updated review suggests that patient education, monitoring and supervision, change in drug regimen, and interdisciplinary collaboration have mixed results on medication adherence and persistence, with more positive effects for multicomponent interventions with active patient involvement. Compared with the previous review, a shift towards more patient involvement, counseling and shared decision-making, was seen, suggesting that individualized solutions, based on collaboration between the patient and the healthcare provider, are needed to improve adherence and persistence to osteoporosis medications.

Keywords: Adherence; Counseling; Education; Osteoporosis; Patient; Persistence.

PubMed Disclaimer

Conflict of interest statement

Jean-Yves Reginster has received research grants from IBSA-Genévrier, Mylan, CNIEL, and Radius Health through institution, has received advisory board or consulting fees from IBSA-Genévrier, Mylan, Radius Health, and Pierre Fabre, and has received lecture fees from IBSA-Genévrier, Mylan, CNIEL, and Dairy Research Council (DRC). Mickaël Hiligsmann has received research grants from Amgen, Bayer, Radius Health, and Theramex through institution. The other authors have no conflict of interest relevant to the content of this study.

Figures

Fig. 1
Fig. 1
PRIMSA flow chart
See this image and copyright information in PMC

References

    1. Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8. 10.1007/s11657-013-0136-1 - PMC - PubMed
    1. Lötters FJB, van den Bergh JP, de Vries F, et al. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int. 2016;98:235–243. doi: 10.1007/s00223-015-0089-z. - DOI - PMC - PubMed
    1. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23–57. doi: 10.1007/s00198-012-2074-y. - DOI - PMC - PubMed
    1. Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM, van Onzenoort H, Leufkens HG, Bijlsma JW, de Vries F. Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int. 2015;26:1831–1840. doi: 10.1007/s00198-015-3084-3. - DOI - PMC - PubMed
    1. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in the Netherlands. Osteoporos Int. 2011;22:1537–1546. doi: 10.1007/s00198-010-1372-5. - DOI - PMC - PubMed

Publication types